Conscious of difficulties in the translation of in vitro and in vivo results of immune therapy effectiveness to the clinical application, we utilized the RCAS/tv-a system to generate PDGFB-induced gliomas with or without p53 knockdown. Here, TP53 is linked to central nervous system cancer.